Construction of KHV‐CJ ORF25 DNA vaccine and immune challenge test

KHV ORF25 fragments were cloned from Koi Herpes Virus‐CJ (KHV‐CJ) strains isolated in our laboratory. The amplified products were inserted into the eukaryotic expression vector pIRES‐neo, forming recombinant plasmid pIRES‐ORF25. The recombinant plasmid pIRES‐ORF25 at 1 μg per koi, 10 μg per koi and 50 μg per koi was intramuscularly injected into healthy kois, respectively. The results showed that the recombinant pIRES‐ORF25 could induce the production of specific antibodies in koi determined by indirect ELISA. The differences of immune effect between three doses were not significant (P > 0.05), but all of them could induce the production of neutralizing antibodies. The immune challenge test showed that the mortality of koi injected with PBS, blank pIRES‐neo vector and nothing was 90%, 92.5% and 85% at 25 days. While the mortalities of koi injected with eukaryotic expression plasmid pIRES‐ORF25 were 20%, 17.5% and 12.5%. Differences in comparison with the control group were highly significant (P < 0.01). Histopathological staining revealed that the tissues of the immunized koi did not change apparently. In conclusion, the DNA vaccine pIRES‐ORF25 construct could well protect koi against KHV and had the potential to be applied in practice.